富临精工：子公司江西升华出资2.7亿元设立合资公司 2月3日晚，富临精工(300432)发布公告称，公司子公司江西升华新材料有限公司与贵州大龙汇成新材料 有限公司签订《项目投资合作协议》，共同投资设立合资公司，新建年产50万吨草酸亚铁项目。目标公 司注册资本为3亿元，其中江西升华出资2.7亿元，持股90%；大龙汇成出资3000万元，持股10%。项目 预计总投资额度15亿元，计划于2026年9月30日前建成投产。 旭光电子：拟定增募资不超过10亿元 2月3日晚，旭光电子(600353)发布公告称，公司2026年度拟向特定对象发行A股股票募集资金总额不超 过10亿元，扣除发行费用后将全部用于高压（72.5kV及以上）真空灭弧室扩能项目、等离子体加热大功 率发射管、回旋管及瞬态能量管理开关研发及产业化项目及补充流动资金项目。 民爆光电：拟收购厦芝精密100%股权 2月3日晚，民爆光电(301362)发布公告称，公司股票于2026年2月2日、2026年2月3日连续两个交易日收 盘价涨跌幅累计偏离43.92%，根据深圳证券交易所交易规则，属于股票交易异常波动。公司拟以现金 和发行股份两种方式收购厦芝精密100%股权。该 ...

亨迪药业公告，近日收到国家药品监督管理局核准签发的关于盐酸埃克替尼的《化学 原料药上市申请 批准通知书》（证书编号：2026YS00095）。盐酸埃克替尼是我国自主研发的EGFR酪氨酸激酶抑制剂 类靶向药，主要用于治疗表皮生长因子受体（EGFR）基因存在敏感突变的局部晚期或转移性非小细胞 肺癌，也可用于既往化疗失败的晚期非小细胞肺癌患者的治疗。 ...

格隆汇2月3日丨亨迪药业(301211.SZ)公布，近日收到国家药品监督管理局核准签发的关于盐酸埃克替 尼的《化学原料药上市申请批准通知书》。盐酸埃克替尼是我国自主研发的EGFR酪氨酸激酶抑制剂类 靶向药，主要用于治疗表皮生长因子受体（EGFR）基因存在敏感突变的局部晚期或转移性非小细胞肺 癌，也可用于既往化疗失败的晚期非小细胞肺癌患者的治疗。 ...

据悉，盐酸埃克替尼是EGFR酪氨酸激酶抑制剂类靶向药，主要用于治疗表皮生长因子受体(EGFR)基因 存在敏感突变的局部晚期或转移性非小细胞肺癌，也可用于既往化疗失败的晚期非小细胞肺癌患者的治 疗。 亨迪药业（301211）(301211.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于盐酸埃克替 尼的《化学原料药上市申请批准通知书》。 ...

智通财经APP讯，亨迪药业(301211.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于盐酸埃 克替尼的《化学原料药上市申请批准通知书》。 据悉，盐酸埃克替尼是 EGFR酪氨酸激酶抑制剂类靶向药，主要用于治疗表皮生长因子受体(EGFR)基 因存在敏感突变的局部晚期或转移性非小细胞肺癌，也可用于既往化疗失败的晚期非小细胞肺癌患者的 治疗。 ...

Core Viewpoint - The article highlights the dedication and contributions of Gao Yaqin, a quality engineer at Betta Pharmaceuticals, who has been instrumental in ensuring the quality of innovative drugs, particularly the first small molecule targeted cancer drug in China, for over fifteen years [1][3]. Group 1: Company Background - Betta Pharmaceuticals was established during a time when generic drugs dominated the market, with a small team focused on developing China's first small molecule targeted anti-cancer drug [3]. - The company successfully launched the drug, Erlotinib Hydrochloride, in 2011, which won the National Science and Technology Progress Award [3]. Group 2: Quality Control Achievements - Gao Yaqin has maintained a 100% accuracy rate in quality inspections over her fifteen-year career, demonstrating exceptional professional skills and experience [6]. - The rigorous quality control processes led to the successful market entry of Erlotinib Hydrochloride, benefiting approximately 700,000 lung cancer patients [6]. Group 3: Problem-Solving and Team Leadership - Gao Yaqin's proactive approach in identifying discrepancies in product data has prevented potential quality issues, showcasing her critical role in the quality assurance process [4]. - She led her team in a thorough investigation to resolve a data anomaly, ensuring that a batch of hundreds of kilograms of medicine was cleared for market release after confirming its quality [6].

Group 1 - The core viewpoint of the news is that Hongdao Investment has conducted research on the listed company Betta Pharmaceuticals, highlighting its financial performance and product pipeline for 2024 [1] - In 2024, Betta Pharmaceuticals is projected to achieve a revenue of 2,891.95 million yuan, representing a year-on-year growth of 17.74%, and a net profit attributable to shareholders of 402.57 million yuan, with a growth of 15.67% [1] - The company has successfully launched five new drugs, including Acetylcysteine, Ensartinib capsules, Bevacizumab, and others, with Bemetanib receiving FDA approval and being included in the NCCN guidelines [1] Group 2 - Betta Pharmaceuticals has invested 717 million yuan in R&D for 2024, accounting for 24.80% of its revenue, with multiple new drug developments progressing smoothly [1] - The company is collaborating with several enterprises to introduce new drugs and expand its R&D pipeline, aiming to build an innovative pharmaceutical ecosystem [1]

Group 1: Beida Pharmaceutical - In 2024, Beida Pharmaceutical achieved operating revenue of 2,891.95 million yuan, a year-on-year increase of 17.74%, and a net profit attributable to shareholders of 402.57 million yuan, up 15.67% year-on-year [1] - The company has launched five new drugs, including Acetylcysteine, Ensartinib capsules, Bevacizumab, and others, with Beimu approved by the FDA and included in the NCCN guidelines [1] - R&D investment for 2024 is 717 million yuan, accounting for 24.80% of revenue, with multiple new drug developments progressing smoothly [1] Group 2: East China Pharmaceutical - East China Pharmaceutical is actively advancing product R&D and market layout across multiple fields, with GLP-1 series products entering Phase III clinical trials, expecting significant results by 2025 [2] - The company has several innovative products in the ADC and PROTAC fields, with some already in clinical stages [2] - East China Pharmaceutical is confident in the overseas medical beauty market and is actively pursuing overseas registration for its medical beauty products [2]